Kaplan-Meier for progression-free survival (PFS) and for overall survival (OS) among patients who received FOLFORI and AZD8931 160 mg bd.
deaths, death
EVENTS, DISEASE PROGRESSION
PFS events were defined as disease progression or death, whichever occurred first. OS events include deaths from any cause. Number at risk are given under the plot.Among this group, the median PFS time was 8.7 months, and the 12 and 24 months PFS rate was 25% (6–50%) and 17% (3–41%), respectively; the median OS was 21.2 months, and the 12- and 24-month OS rate 67% (34–86%) and 50% (21–74%), respectively. Patients who received any AZD dose presented improved OS when compared to patients who received FOLFIRI alone (Supplementary Fig. 